JP2007508238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508238A5 JP2007508238A5 JP2006518009A JP2006518009A JP2007508238A5 JP 2007508238 A5 JP2007508238 A5 JP 2007508238A5 JP 2006518009 A JP2006518009 A JP 2006518009A JP 2006518009 A JP2006518009 A JP 2006518009A JP 2007508238 A5 JP2007508238 A5 JP 2007508238A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- chr
- independently
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052717 sulfur Inorganic materials 0.000 claims 26
- 229910052760 oxygen Inorganic materials 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000004432 carbon atom Chemical group C* 0.000 claims 21
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 125000005842 heteroatom Chemical group 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical class NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 claims 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000004122 cyclic group Chemical group 0.000 claims 7
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 4
- 108091000080 Phosphotransferase Proteins 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 102000020233 phosphotransferase Human genes 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 3
- 101150065749 Churc1 gene Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 102100038239 Protein Churchill Human genes 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 102000009929 raf Kinases Human genes 0.000 claims 3
- 108010077182 raf Kinases Proteins 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- -1 alkylenecycloalkyl Chemical group 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229910021645 metal ion Inorganic materials 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 101150019464 ARAF gene Proteins 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 claims 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000003584 mesangial cell Anatomy 0.000 claims 1
- 230000006371 metabolic abnormality Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000644 propagated effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03014556 | 2003-07-07 | ||
| EP03014556.9 | 2003-07-07 | ||
| PCT/EP2004/006573 WO2005005389A2 (en) | 2003-07-07 | 2004-06-18 | Malonamide derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007508238A JP2007508238A (ja) | 2007-04-05 |
| JP2007508238A5 true JP2007508238A5 (OSRAM) | 2007-08-23 |
| JP4750701B2 JP4750701B2 (ja) | 2011-08-17 |
Family
ID=34042809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006518009A Expired - Fee Related JP4750701B2 (ja) | 2003-07-07 | 2004-06-18 | マロンアミド誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070213374A1 (OSRAM) |
| EP (1) | EP1641759B1 (OSRAM) |
| JP (1) | JP4750701B2 (OSRAM) |
| AR (1) | AR045033A1 (OSRAM) |
| AU (1) | AU2004255566B2 (OSRAM) |
| CA (1) | CA2531485C (OSRAM) |
| WO (1) | WO2005005389A2 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| HRP20060073B1 (hr) | 2003-07-23 | 2014-03-14 | Bayer Healthcare Llc | Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja |
| WO2005030140A2 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
| EP1719763A4 (en) | 2004-02-27 | 2008-01-09 | Eisai R&D Man Co Ltd | NEW PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) |
| UA85087C2 (en) * | 2004-04-23 | 2008-12-25 | Бристол-Майэрс Сквибб Компани | Monocyclic heterocycles as kinase inhibitors |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| EP1773826A4 (en) * | 2004-07-02 | 2009-06-03 | Exelixis Inc | MODULATORS OF C-MET AND THEIR METHOD OF USE |
| US7470693B2 (en) | 2005-04-21 | 2008-12-30 | Bristol-Myers Squibb Company | Oxalamide derivatives as kinase inhibitors |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| WO2007023768A1 (ja) | 2005-08-24 | 2007-03-01 | Eisai R & D Management Co., Ltd. | 新規ピリジン誘導体およびピリミジン誘導体（３） |
| ES2375284T3 (es) | 2006-08-23 | 2012-02-28 | Eisai R&D Management Co., Ltd. | Sal de un derivado de fenoxipiridina, o cristal de la misma, y procedimiento de producción de la misma. |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| DK2387563T4 (da) | 2009-01-16 | 2022-07-18 | Exelixis Inc | Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| TWI520962B (zh) * | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
| CN110072526A (zh) * | 2016-08-17 | 2019-07-30 | 西奈山伊坎医学院 | 治疗癌症的激酶抑制剂化合物、组合物和方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3574249D1 (en) * | 1984-02-08 | 1989-12-21 | Sawai Seiyaku Kk | Û(1,3,-dioxo-1,3-propanediyl)diimino¨ bisbenzoic acid derivatives and their use |
| JP3380237B2 (ja) * | 1988-09-12 | 2003-02-24 | ファルマシア・アンド・アップジョン・カンパニー | ２のｃｐｉサブユニットを有する新規ｃｃ―１０６５アナログ類 |
| JP2627238B2 (ja) * | 1992-12-02 | 1997-07-02 | 富士写真フイルム株式会社 | マロン酸ジアミド化合物の製造方法 |
| JPH08295667A (ja) * | 1995-04-27 | 1996-11-12 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および剤 |
| NZ505844A (en) * | 1997-12-22 | 2003-10-31 | Bayer Ag | Inhibition of raf kinase using substituted heterocyclic ureas |
| JP4261639B2 (ja) * | 1998-08-05 | 2009-04-30 | 日本曹達株式会社 | フェニルイミダゾール系抗高脂血症薬 |
| WO2000026197A1 (en) * | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Novel inhibitors of impdh enzyme |
| WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| JP3528152B2 (ja) | 2000-01-17 | 2004-05-17 | 有限会社ひので屋 | 豆腐製造用撹拌器具 |
| US6916846B2 (en) * | 2000-05-12 | 2005-07-12 | Merck & Co. Inc. | Coumermycin analogs as chemical dimerizers of chimeric proteins |
| WO2002044126A2 (en) * | 2000-11-28 | 2002-06-06 | Guilford Pharmaceuticals Inc. | Bisubstituted carbocyclic cyclophilin binding compounds and theirus |
| DE10112771A1 (de) * | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| KR100883731B1 (ko) | 2001-06-22 | 2009-02-12 | 기린 파마 가부시끼가이샤 | 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물 |
| CA2488642C (en) * | 2002-06-27 | 2011-09-06 | Dharma Rao Polisetti | Aryl carbonyl derivatives as glucokinase activators |
| ES2311120T3 (es) * | 2002-08-27 | 2009-02-01 | Merck Patent Gmbh | Derivados de glicinamida como inhibidores de quinasa-raf. |
| PL374758A1 (en) * | 2002-10-24 | 2005-10-31 | Merck Patent Gmbh | Methylene urea derivatives |
| WO2004058234A2 (en) * | 2002-12-27 | 2004-07-15 | Schering Aktiengesellschaft | Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
-
2004
- 2004-06-18 US US10/563,830 patent/US20070213374A1/en not_active Abandoned
- 2004-06-18 JP JP2006518009A patent/JP4750701B2/ja not_active Expired - Fee Related
- 2004-06-18 EP EP04740026.2A patent/EP1641759B1/en not_active Expired - Lifetime
- 2004-06-18 AU AU2004255566A patent/AU2004255566B2/en not_active Ceased
- 2004-06-18 WO PCT/EP2004/006573 patent/WO2005005389A2/en not_active Ceased
- 2004-06-18 CA CA2531485A patent/CA2531485C/en not_active Expired - Fee Related
- 2004-07-07 AR ARP040102386A patent/AR045033A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007508238A5 (OSRAM) | ||
| KR101882328B1 (ko) | 거세-저항성 전립선 암 및 골형성성 뼈전이의 치료용 met 및 vegf 이중 억제제들 | |
| EP2253625B1 (en) | Pyridazinones, the preparation and the use thereof | |
| RU2005115842A (ru) | Производные метиленмочевины | |
| JP2024514703A (ja) | ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用 | |
| JP2004509113A5 (OSRAM) | ||
| RU2013122898A (ru) | Похоксимовые конъюгаты, применимые для лечения связанных с hsp90 патологий, композиция и способ лечения с их помощью | |
| JP2020528889A5 (OSRAM) | ||
| JP2012514044A5 (OSRAM) | ||
| JP2004529140A5 (OSRAM) | ||
| JP2013537171A (ja) | 複素環アミノベルバミン誘導体、その調製方法及び使用 | |
| JP2006522824A5 (OSRAM) | ||
| JP2020528877A (ja) | 新規化合物及びそれを有効成分として含有する、線維症または非アルコール性脂肪肝炎の予防、改善または治療用組成物 | |
| US10947225B2 (en) | Phosphotidylinositol 3-kinase inhibitors | |
| JP2025526504A (ja) | エキサテカン誘導体及びその使用 | |
| CA2652811A1 (en) | Potentiator of radiation therapy | |
| JP6913955B2 (ja) | ＰＩ３Ｋ／ｍＴＯＲ阻害剤としての溶融キノリン化合物 | |
| JPWO2021076691A5 (OSRAM) | ||
| JP2010111702A (ja) | 複素環化合物、その製造法および用途 | |
| JP2015523349A (ja) | ポリフィリンｉのアシル化誘導体、その調製方法及び使用 | |
| JP2023526443A (ja) | Ｒｏｎ変異が関与する非小細胞肺がんの予防又は治療用医薬組成物及びその使用方法 | |
| JP7506948B2 (ja) | テトラジン置換基を含むアロイソセレナゾール化合物及びその合成方法と応用 | |
| KR102778078B1 (ko) | 피라졸 유도체 및 이의 용도 | |
| RU2016137761A (ru) | Оксепан-2-ил-пиразол-4-ил-гетероциклил-карбоксамиды и способы их применения | |
| JP2025518115A (ja) | 急性炎症を治療するためのピリミジノン化合物 |